摘要
目的探究大剂量静注人免疫球蛋白联合七叶皂甙钠治疗吉兰-巴雷综合征(GBS)的临床应用价值。方法回顾性选取2015年2月至2018年3月于我院治疗的40例GBS患者为研究对象,仅采用大剂量静注人免疫球蛋白治疗的20例患者列为单一组,采用大剂量静注人免疫球蛋白联合七叶皂甙钠治疗的20例患者列为联合组。对比两组患者的Fugl-Meyer评分、Barthel量表评分、疗效以及不良反应发生情况。结果治疗1、2、3周后,两组的Fugl-Meyer评分均升高,且联合组显著高于单一组(P<0.05)。治疗1、2、3周后,两组患者的Barthel评分均升高,且联合组显著高于单一组(P<0.05)。联合组的治疗总有效率明显高于单一组(P<0.05)。单一组不良反应总发生率为5.00%,联合组不良反应总发生率为5.00%,两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论大剂量静注人免疫球蛋白联合七叶皂甙钠治疗GBS可显著改善患者临床症状,提升患者运动能力与自理能力,因此具备临床推广价值。
Objective To explore the clinical effect of high dose human immunoglobulin for intravenous injection combined with sodium aescinate in the treatment of Guillain-Barre syndrome (GBS). Methods A total of 40 patients with GBS treated in our hospital from February 2015 to March 2018 were retrospectively selected as study objects. Twenty patients treated with high dose human immunoglobulin for intravenous injection were classified as single group and 20 patients treated with high dose human immunoglobulin for intravenous injection combined with sodium aescinate as combined group. The scores of Fugl-Meyer, Barthel scale, efficacy and adverse reactions were compared between the two groups. Results After 1, 2 and 3 weeks of treatment, the Fugl-Meyer scores of the two groups increased, and those of the combined group were significantly higher than the single group (P<0.05). After 1, 2 and 3 weeks of treatment, the Barthel scores of both groups increased, and those of the combined group were significantly higher than the single group (P<0.05). The total effective rate of treatment in the combined group was significantly higher than that in the single group (P<0.05). The total incidence of adverse reactions was 5.00% in the single group and 5.00% in the combined group. There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion High dose human immunoglobulin for intravenous injection combined with sodium aescinate can significantly improve the clinical symptoms, athletic ability and self-care ability of patients with GBS, so it has clinical popularization value.
作者
韩涛
张杰
福婷
陈鹏
王玉
HAN Tao;ZHANG Jie;FU Ting;CHEN Peng;WANG Yu(Xianyang Central Hospital,Xianyang 712000;People's Hospital of Tongchuan,Tongchuan 727000,China)
出处
《临床医学研究与实践》
2019年第21期3-4,20,共3页
Clinical Research and Practice
基金
铜川市科技研究社发攻关项目(No.KJ2014-03)
关键词
静注人免疫球蛋白
七叶皂甙钠
吉兰-巴雷综合征
human immunoglobulin for intravenous injection
sodium aescinate
Guillain-Barre syndrome
